| Literature DB >> 31852449 |
Takeo Ishii1,2, Shizuka Takabe3, Yuki Yanagawa3, Yuko Ohshima3, Yasuhiro Kagawa3, Atsuko Shibata3, Kunio Oyama3.
Abstract
BACKGROUND: A simpler method for detecting atherosclerosis obliterans is required in the clinical setting. Laser Doppler flowmetry (LDF) is easy to perform and can accurately detect deterioration in skin perfusion. We performed LDF for hemodialysis patients to determine the correlations between blood flow in the lower limbs and peripheral arterial disease (PAD).Entities:
Keywords: Laser doppler flowmetry; Peripheral arterial disease; Skin perfusion pressure
Mesh:
Year: 2019 PMID: 31852449 PMCID: PMC6921472 DOI: 10.1186/s12882-019-1653-y
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Patient characteristics
| Non-PAD ( | PAD ( | ||||||
|---|---|---|---|---|---|---|---|
| Age (year) | 59.8 | (50.0, 70.0) | 71.8 | (64.0,81.0) | 0.0004 | ||
| Dialysis Vintage (years) | 7.0 | (3.0, 14.0) | 9.0 | (7.0, 11.0) | NS | ||
| BMI (kg/m2) | 23.2 | ± | 4.4 | 22.1 | ± | 4.5 | NS |
| Yes | No | Yes | No | ||||
| DM (y/n %) | 30 | 76 | 28.30% | 13 | 9 | 59.10% | 0.0115 |
| Sex (male/female) | 19 | 87 | 82.10% | 4 | 18 | 81.80% | NS |
| SBP (mmHg) | 149.3 | ± | 21.3 | 146.2 | ± | 21.9 | NS |
| DBP (mmHg) | 81 | ± | 13.7 | 71.3 | ± | 13.5 | 0.0056 |
| Online HDF (y/n) | 16 | 106 | 15.10% | 3 | 22 | 13.60% | NS |
| Total Fluid Removal (kg) | 3.3 | 2.7 | 3.8 | 2.6 | 2.2 | 3.4 | 0.0134 |
| KtV | 1.4 | (1.4, 1.5) | 1.4 | 1.3 | 1.5 | 0.893 | |
| CGR (%) | 104.8 | (100.0, 109.6) | 86.3 | (78.3, 94.3) | 0.0002 | ||
| nPCR (g/kg/day) | 0.9 | (0.9, 1.0) | 0.8 | (0.8, 0.9) | 0.006 | ||
| Anticoagulant for dialysis n (%) | Hepaline | Low Molecular | Nafamostat | Hepaline | Low Molecular | Nafamostat | |
| 77 / 72.6% | 22 / 20.8% | 6 / 5.7% | 11 / 50.0% | 7 / 31.8% | 6 / 5.7% | ||
| Fontaine grade I n (%) | 99 | 93.40% | 8 | 36.40% | |||
| Fontaine grade II n (%) | 7 | 6.60% | 3 | 13.60% | |||
| Fontaine grade III n (%) | 0 | 0% | 5 | 22.70% | |||
| Fontaine grade IV n (%) | 0 | 0% | 6 | 27.30% | |||
| Hb (g/dL) | 11.2 | ± | 0.9 | 10.8 | ± | 1.2 | NS |
| Ht (%) | 34.5 | ± | 2.8 | 34 | ± | 4.0 | NS |
| Fe (μg/dL) | 76.1 | ± | 22.5 | 61.7 | ± | 22.2 | 0.0114 |
| Ferritin (ng/mL) | 41.5 | (20.3, 81.7) | 60.3 | (28, 106.3) | NS | ||
| TSAT (%) | 26.8 | (21.7, 33.9) | 24.3 | (16.5, 29.8) | NS | ||
| BUN (mg/dL) | 68.2 | (65.5, 70.9) | 58.6 | (51.8, 65.4) | 0.0111 | ||
| Cr (g/dL) | 12.5 | (11.9, 13.0) | 9.5 | (8.5, 10.5) | < 0.0001 | ||
| UA (mg/dL) | 7.6 | (6.6, 8.5) | 7.2 | (5.6, 7.9) | 0.0326 | ||
| CRP (ng/mL) | 0.2 | (0.1, 0.4) | 0.5 | (0.1, 1.2) | 0.0104 | ||
| Na (mEq/L) | 139.2 | (137.3, 140.5) | 137.5 | (136.2, 139.2) | NS | ||
| K (mEq/L) | 4.9 | (4.5, 5.2) | 4.4 | (4.2, 4.8) | 0.004 | ||
| Cl (mEq/L) | 101.7 | (100,0103.3) | 101.7 | (100, 104.0) | NS | ||
| Pi (mg/dL) | 5.6 | (5.4, 5.9) | 5.1 | (4.6, 5.7) | 0.1148 | ||
| Ca (mg/dL) | 8.5 | (8.1, 9.2) | 8.2 | (7.9, 8.6) | NS | ||
| iPTH (pg/mL) | 254.5 | (224.4, 284.7) | 264.9 | (194.2, 335.6) | 0.7828 | ||
| Alb (g/mL) | 3.7 | (3.6, 3.7) | 3.3 | (3.1, 3.5) | 0.0003 | ||
| Ret (%0) | 16.1 | (15, 17.1) | 16.8 | (13.5, 20.1) | 0.6495 | ||
| TP (g/dL) | 7.0 | (6.7, 7.2) | 6.9 | (6.7, 7.3) | NS | ||
| Tcho (mg/dL) | 164.9 | (158.7, 171.2) | 137.8 | (127.1, 148.4) | < 0.0001 | ||
| TG (mg/dL) | 143.1 | (125.0, 161.3) | 94.7 | (74.3, 115.2) | 0.0006 | ||
| LDL (mg/dL) | 88.0 | (74.0, 114.5) | 68.3 | (58.8, 82.3) | 0.003 | ||
| HDL (mg/dL) | 47.9 | (45.1, 50.7) | 45.8 | (39.7, 51.9) | 0.5126 | ||
| β2MG (mg/L) | 28.1 | (26.9, 29.2) | 31.1 | (28.1, 34.1) | 0.061 | ||
| ESA dose (μg/week) | 6.6 | (3.0, 10.0) | 11.3 | (4.2, 17.8) | NS | ||
| Vitamin D (μg/week) | 0.0 | (0.0, 2.5) | 0.0 | (0.0, 2.5) | NS | ||
| Cinacalcet (mg/week) | 0.0 | (0.0350.0) | 87.5 | (0.0350.0) | NS | ||
| Yes | No | Yes (%) | Yes | No | Yes (%) | ||
| Ca antagonist (y/n) | 62 | 44 | 58.50% | 5 | 17 | 22.70% | 0.0041 |
| ACE/ARB (y/n) | 30 | 76 | 28.30% | 5 | 17 | 22.70% | NS |
| Alpha blocker (y/n) | 5 | 101 | 4.70% | 2 | 20 | 9.10% | NS |
| Alpha beta blocker (y/n) + B35 | 35 | 71 | 30.00% | 6 | 16 | 27.30% | NS |
| Aspirin (y/n) | 21 | 85 | 19.80% | 9 | 13 | 40.90% | 0.0506 |
| Ticlopidine hydrochloride (y/n) | 3 | 103 | 2.80% | 0 | 22 | 0.00% | NS |
| Clopidogrel sulfate (y/n) | 8 | 98 | 7.60% | 4 | 18 | 18.20% | NS |
| Cilostazol (y/n) | 1 | 105 | 0.90% | 3 | 19 | 13.60% | 0.016 |
Systolic Bp, Alb, Cr, and other covariates were decreased in the PAD group.
SPP skin perfusion pressure, LDF laser Doppler flowmetry, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, Hb hemoglobin, HT hypertension, TSAT transferrin saturation, BUN blood urea nitrogen, Cr creatinine, UA uric acid, CRP C-reactive protein, iPTH intact parathyroid hormone, Alb albumin, TP total protein, Tcho total cholesterole, TG triglycerides, LDL low-density lipoprotein, HDL high-density lipoprotein, β2MG beta-2 microglobulin, KtV measure of dialysis, CGR creatinine generation rate, nPCR normalized protein catabolic rate, ESA erythropoiesis-stimulating agent, DM diabetes mellitus, ACE angiotensin-converting enzyme, inhibitor, ARB angiotensin receptor blocker, NS not significant, y/n yes/no.
Data are presented as n(%), mean ± sd, or median (interquartile range)
Measurements of the lower limbs of dialysis patients in the non-PAD and PAD groups
| SPP mmHg | PAD (−) ( | PAD (+) ( | |||
|---|---|---|---|---|---|
| mean | sd | mean | sd | ||
| SPP-Dorsal-Area | 82.1 | 22.0 | 59.1 | 20.3 | |
| SPP-Plantar-Area | 80.1 | 20.2 | 66.0 | 24.3 | |
| LDF | median | quartile range | median | quartile range | |
| LDF-Dorsal-Qb | 10.7 | (8.4, 14.6) | 12.0 | (8.1, 16.3) | NS |
| LDF-Plantar-Qb | 30.3 | (19.7, 43.5) | 21.5 | (15.0, 26.8) | |
| LDF-Dorsal-PA | 3.1 | (2.2, 4.2) | 2.2 | (1.3, 4.2) | NS |
| LDF-Plantar-PA | 7.9 | (5.0, 12.2) | 5.2 | (2.1, 7.3) | |
| LDF-Dorsal-PR | 77.1 | (70.7, 83.3) | 79.2 | (79.2, 72.9) | NS |
| LDF-Plantar-PR | 74.3 | (74.3, 66.6) | 78.3 | (78.3, 69.9) | NS |
Each measurement was performed in the dorsal area and palmar area, and values were indicated as an average of the right and left.
PAD peripheral arterial disease, SPP skin perfusion pressure, D dorsal area of the foot, P plantar area of the foot, LDF laser Doppler flowmetry, saturation, Qb blood flow (mL / min), PA (mL / min), pulse amplitude PR (bpm), pulse rate, NS not significant, CI confidence interval, SD standard deviation
Data are presented mean ± sd, or median (interquartile range)
Fig. 1Comparison of the non-PAD and PAD groups using SPP and LDF measurements in the dorsal area. *Statistical significance (p < 0.05)
Fig. 2Differences in LDF-Qb for the non-PAD and PAD groups in the plantar area. *Statistical significance (p < 0.05)
Fig. 3a SPP values for the plantar area divided by Fontaine stage. Fontaine stage III and IV were significantly decreased compared with Fontaine grade I in SPP, but stage II was not significant. *Statistical significance (p < 0.05). b LDF values for the plantar area divided by Fontaine stage. Fontaine stage II was 24.5 +/− 18.0 ml/min decreased from 32.8 +/− 15.0 ml/min
Multivariate logistic regression (stepwise method) for PAD using SAS®
| Multivariate logistic regression (SPP) | ||||
| Covariate | p | Odds ratio | Lower limit | Upper limit |
| SPP-Dorsal Area | 0.0244 | 0.97 | 0.94 | 1.00 |
| Cr | 0.0095 | 0.72 | 0.56 | 0.92 |
| CRP | 0.0325 | 2.62 | 1.18 | 6.94 |
| Tcho | 0.0103 | 0.97 | 0.94 | 0.99 |
| Multivariate logistic regression (laser Doppler) | ||||
| Covariate | p | Odds ratio | Lower limit | Upper limit |
| LDF-Plantar-Qb | 0.026 | 0.94 | 0.87 | 0.99 |
| Cr | 0.0008 | 0.65 | 0.49 | 0.82 |
| CRP | 0.0221 | 3.08 | 1.27 | 8.74 |
| Tcho | 0.0176 | 0.97 | 0.94 | 0.99 |
Skin perfusion pressure (SPP) and laser Doppler (LD) confounded each other; therefore, divided regression was performed.
PAD peripheral arterial disease, D dorsal area of the foot, P plantar area of the foot, Cr creatinine, CRP C-reactive protein, Tcho total choline
Fig. 4ROC curves of LDF-Plantar-Qb for PAD (adjusted for C-reactive protein, creatinine, total cholesterol). Sensitivity, 0.88; specificity, 0.78; cut-off, 20.0 mL/min using Youden’s index method (Additional file 2: Table S4). PAD(−). without peripheral arterial disease; PAD(+) with peripheral arterial disease; SPP, skin perfusion pressure; LDF, Laser Doppler flowmetry; LDF-Dorsal-Qb, LDF blood flow rate in the dorsal area of the foot; LDF-Plantar-Qb, LDF blood flow rate in the plantar area of the foot; LDF-Qb, LDF blood flow rate; SPP-Dorsal Area, skin perfusion pressure in the dorsal area of the foot; ROC, receiver-operating characteristic